Clinical Trial Results, Licensing Agreements, Breakthrough Research and Development Programs - Research Report on Pfizer, Merck, Rockwell Medical, GlaxoSmithKline, and Novartis

NEW YORK, September 18, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Rockwell Medical Technologies Inc. (NASDAQ: RMTI), GlaxoSmithKline plc (NYSE: GSK), and Novartis AG (NYSE: NVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On September 3, 2013, Pfizer Inc. (Pfizer) and Bristol-Myers Squibb Company (Bristol-Myers) announced results of a post-hoc subanalysis of Phase III ARISTOTLE trial, demonstrating the efficacy and safety of Eliquis compared to warfarin for the prevention of stroke or systemic embolism in nonvalvular atrial fibrillation (NVAF) patients. According to the Company, the results from the subanalysis were consistent with the overall ARISTOTLE trial and demonstrated that Eliquis compared with warfarin reduced stroke or systemic embolism, caused fewer major bleeding events, and reduced all-cause mortality in NVAF patients with or without VHD. "This subanalysis provides better insight into the efficacy and safety of apixaban in nonvalvular atrial fibrillation patients with certain types of valvular heart disease, which are common in an elderly population," said Study Lead Author Dr. Alvaro Avezum of the Dante Pazzanese Institute of Cardiology in San Paulo, Brazil. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Merck & Co. Inc. Research Report  

On September 11, 2013, Merck & Co. Inc (Merck) and AstraZeneca, announced a worldwide licensing agreement for Merck's oral small molecule inhibitor of WEE1 kinase (MK-1775), which is currently being evaluated in Phase IIa clinical studies in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer. Pursuant to the terms of the agreement, Merck will receive a $50 million upfront fee from AstraZeneca, along with contingent future payments related to the development and regulatory milestones, plus sales related payments and tiered royalties. Further, as per the agreement, AstraZeneca will be responsible for all future clinical development, manufacturing and marketing. The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Rockwell Medical Technologies Inc. Research Report

On September 4, 2013, Rockwell Medical Technologies Inc. (Rockwell Medical) announced successful top-line results from its long-term CRUISE-2 Phase 3 efficacy study of SFP, the Company's late-stage investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. According to the Company, the study met the primary and secondary endpoints, demonstrating a statistically significant mean change in hemoglobin from baseline to End-of-Treatment. The Company further stated that the study is the second and final study of two identical Phase 3 efficacy studies to provide clinical data required for the Company to file a New Drug Application (NDA) with the US FDA. Rob Chioini, Founder, Chairman and CEO of Rockwell Medical stated, "As we were with CRUISE-1, we are thrilled with the successful outcome of this CRUISE-2 efficacy study. This second Phase 3 study produced identical results to the first in demonstrating statistical significance and meeting the primary efficacy endpoint." The Full Research Report on Rockwell Medical Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


GlaxoSmithKline plc Research Report

On September 12, 2013, GlaxoSmithKline plc's (GlaxoSmithKline) joint venture company with Pfizer, ViiV Healthcare, announced initial results from its Phase IIIb/IV FLAMINGO (ING114915) study. According to the Company, the study compared once-daily regimens containing 50mg dolutegravir with once-daily regimens containing a protease inhibitor (PI) in treatment-naïve adults with HIV-1. The Company stated that in the period of 48 weeks 90% of patients treated with the dolutegravir regimen were virologically suppressed compared to those treated with the darunavir regimen. Dr John Pottage, Chief Medical Officer at ViiV Healthcare said, "This is the first study in our clinical programme to compare dolutegravir to a boosted protease inhibitor in treatment-naïve patients. PIs are often selected as part of a first-line regimen for treatment-naïve patients, so these data provide important information regarding dolutegravir as a treatment choice for these patients." The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Novartis AG Research Report

On September 13, 2013, Novartis AG (Novartis) issued a press release stating that a remarkable progress has been achieved in Malaria programs in sub-Saharan Africa. According to a recent research unveiled at the Tanzania Malaria Control Forum in Dar es Salaam, the rate of malaria among Tanzanian children between ages of six months to five years have reduced to half from 2008 to 2012. Novartis said that these successes have been credited to fighting malaria on several fronts, including scaling up bed nets, diagnostic testing, treatment and surveillance. According to the Company, the Novartis Foundation for Sustainable Development has been working with key stakeholders in Tanzania since 2003, to improve access to quality healthcare while the Novartis Institute for Tropical Diseases (NITD) in Singapore conducts research to develop next generation malaria therapies. Novartis said that taking preventive measures and having access to effective medications, African countries can continue to make progress toward malaria elimination. The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts' Corner